AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Emraclidine was part of AbbVie’s acquisition of Cerevel last year, which also included Tavapadon, which recently reported positive Phase 3 results in Parkinson’s disease. The trial met its ...
Emraclidine was part of AbbVie’s acquisition of Cerevel last year, which also included Tavapadon, which recently reported positive Phase 3 results in Parkinson’s disease. The trial met its primary ...
Furthermore, BMO Capital anticipates that another of AbbVie's products, Tavapadon, which is being developed for Parkinson's disease, still holds promise. The analyst noted that results from the ...
Furthermore, BMO Capital anticipates that another of AbbVie's products, Tavapadon, which is being developed for Parkinson's disease, still holds promise. The analyst noted that results from the ...
Cerevel's pipeline behind emraclidine includes tavapadon, a dopamine D1/D5 partial agonist in phase 3 testing as a treatment for Parkinson’s disease, and darigabat, an α2/3/5-selective GABAA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback